BioPharmSignal logoBioPharmSignal

Biotech News

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

ImmunityBio (IBRX)ImmunityBioCommercial

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC) CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 1, 2026-- ImmunityBio, Inc. ( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster

Related news

IBRXImmunityBio2026-10-08 12:30 EST

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

SNDXSyndax Pharmaceuticals2026-09-01 11:00 EST

Syndax Announces Participation in September Investor Conferences

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

KURAKura Oncology2026-09-08 11:00 EST

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-10-07 11:15 EST

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

RVMDRevolution Medicines2026-09-02 21:50 EST

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

GSKGSK plc2026-09-13 19:30 EST

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer

ARGXArgenx2026-09-29 12:00 EST

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

IDYAIDEAYA Biosciences2026-08-31 10:00 EST

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

View all latest news

ImmunityBio

Immune-Based Cancer Therapies ImmunityBio develops therapies that activate innate and adaptive immune responses against cancer. Its platform combines cytokine biology, cell therapy and immunotherapy combinations. ANKTIVA ANKTIVA is an IL-15 superagonist approved with BCG for selected patients with BCG-unresponsive non-muscle-invasive...

Recent company news

IBRXImmunityBio2026-10-08 12:30 EST

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

IBRXImmunityBio2026-08-10 13:00 EST

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

IBRXImmunityBio2026-08-04 11:30 EST

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

IBRXImmunityBio2026-07-29 22:45 EST

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

IBRXImmunityBio2026-06-01 17:51 EST

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Stock data

Close
9.69 USD
Market cap
7.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States